Explore

Rapid Read Rapid Read
New Breast Cancer Test Enhances Survival Prediction and Treatment

New Breast Cancer Test Enhances Survival Prediction and Treatment

Researchers at Columbia University have developed a new method for diagnosing and grading breast cancer that could significantly impact treatment and survival rates. This approach involves transforming visual patterns of tumor tissues into quantitative measurements using mathematical tools known as topology. The new method provides numerical scores that predict patient survival and treatment response more accurately than traditional biomarkers. This advancement could lead to more personalized treatment decisions by offering a more complete picture of an individual's cancer. The study involved mapping the spatial organization of tumor and immune cells in samples from over 550 breast cancer patients, revealing that topology-based measurements strongly predict survival outcomes.
Rapid Read Rapid Read
DNA Nanorobots Offer Precision in Cancer Treatment by Targeting Tumor Blood Supply

DNA Nanorobots Offer Precision in Cancer Treatment by Targeting Tumor Blood Supply

Researchers have developed DNA nanorobots that can deliver drugs directly to cancer cells, minimizing damage to healthy tissue. These nanorobots, made from DNA origami, are designed to become active only at specific locations, such as tumor-feeding blood vessels. In 2018, a team led by Baoquan Ding and Hao Yan successfully tested these nanorobots in mice, where they patrolled the bloodstream and targeted tumors by shutting off their blood supply without affecting healthy tissue. This approach contrasts with traditional chemotherapy, which affects both cancerous and healthy cells, leading to severe side effects.
Trendline Trendline
N-Zyme Biomedical Raises $4.6 Million to Advance Reflux Disease Treatment

N-Zyme Biomedical Raises $4.6 Million to Advance Reflux Disease Treatment

N-Zyme Biomedical Raises $4.6 Million to Advance Reflux Disease Treatment
Rapid Read Rapid Read
Columbia University Researchers Develop New Breast Cancer Test Using Topology for Improved Survival Predictions

Columbia University Researchers Develop New Breast Cancer Test Using Topology for Improved Survival Predictions

Researchers at Columbia University have developed a novel approach to diagnosing and grading breast cancer by utilizing mathematical tools known as topology. This method transforms visual patterns into quantitative measurements, potentially enhancing the accuracy of predicting breast cancer outcomes and informing treatment decisions. Traditional methods involve examining tissue samples under a microscope to assess changes in tissue and cell structure. The new topology-based biomarkers provide numerical scores that predict patient survival and treatment response more accurately than conventional biomarkers, with less variation across racial and ethnic groups. Dr. Kevin Gardner, a pathologist at Columbia University, emphasized the integration of digital pathology, AI, and machine learning in this research to create a comprehensive understanding of individual cancers. The study involved analyzing tumor samples from over 550 breast cancer patients, revealing that topology-based measurements strongly correlate ...
Trendline Trendline
Cancer Cell Diagnostics Launches Whole-Cell Genomic Profiling to Enhance Liquid Biopsy

Cancer Cell Diagnostics Launches Whole-Cell Genomic Profiling to Enhance Liquid Biopsy

Cancer Cell Diagnostics Launches Whole-Cell Genomic Profiling to Enhance Liquid Biopsy
Trendline Trendline
Amprion Secures Funding to Enhance Neurodegenerative Disease Testing

Amprion Secures Funding to Enhance Neurodegenerative Disease Testing

Amprion Secures Funding to Enhance Neurodegenerative Disease Testing
Trendline Trendline
Verismo Therapeutics Expands Cancer Treatment Pipeline with New CLDN6 Binder

Verismo Therapeutics Expands Cancer Treatment Pipeline with New CLDN6 Binder

Verismo Therapeutics Expands Cancer Treatment Pipeline with New CLDN6 Binder
Rapid Read Rapid Read
Massive Bio and FOMAT Collaborate to Enhance Cancer Patient Access to Clinical Trials

Massive Bio and FOMAT Collaborate to Enhance Cancer Patient Access to Clinical Trials

Massive Bio, a global precision oncology company, has partnered with FOMAT, the largest Embedded Research Organization in the United States, to improve cancer patient prescreening for clinical trials using AI technology. This collaboration, initiated in June 2026, aims to streamline the process of identifying eligible patients for oncology clinical trials across FOMAT's community-based research network. The partnership is currently in a pilot phase, testing the efficiency of integrating AI into the prescreening process. This initiative is designed to reduce the time between diagnosis and trial enrollment, particularly benefiting underserved communities that have historically been underrepresented in clinical research.
Rapid Read Rapid Read
Umeå University Develops Antibody Drug to Halt Aggressive Prostate Cancer Spread

Umeå University Develops Antibody Drug to Halt Aggressive Prostate Cancer Spread

Researchers at Umeå University, in collaboration with other institutions, have developed an experimental antibody drug aimed at slowing tumor growth and preventing the spread of aggressive prostate cancer. The study, published in Signal Transduction and Targeted Therapy, highlights the creation of a fully human antibody designed to prevent metastasis. This antibody, made entirely from human proteins, has shown promise in preclinical studies by stopping tumor growth and metastatic spread in aggressive prostate cancer. The research, led by Professor Maréne Landström, identifies a new mechanism that could potentially lower the risk of side effects. The development of this drug is a significant step towards creating a treatment that could improve survival rates and quality of life for men with advanced prostate cancer.
Rapid Read Rapid Read
Summit 2.0 Test Influences Clinical Decisions in CNS Cancer Cases

Summit 2.0 Test Influences Clinical Decisions in CNS Cancer Cases

Belay Diagnostics has announced that its Summit 2.0 cerebrospinal fluid liquid biopsy test has significantly influenced clinical decision-making in 86% of cases involving central nervous system (CNS) malignancies. The study, co-authored with Johns Hopkins University School of Medicine, surveyed 22 clinicians across 17 institutions. The test was found to aid in diagnosis, treatment selection, and prognosis, even when no genetic variants were detected. The Summit 2.0 test provides a non-invasive alternative to traditional tissue biopsies, offering valuable molecular insights from a standard lumbar puncture.
Rapid Read Rapid Read
Columbia University Researchers Develop New Breast Cancer Diagnostic Method with Topology

Columbia University Researchers Develop New Breast Cancer Diagnostic Method with Topology

Researchers at Columbia University have introduced a novel approach to diagnosing and grading breast cancer by utilizing mathematical tools known as topology. This method transforms visual patterns into quantitative measurements, potentially improving the accuracy of predicting breast cancer outcomes and tailoring treatment plans. Traditionally, breast cancer diagnosis involves examining tissue samples under a microscope to identify structural changes. The new topology-based biomarkers provide numerical scores that predict patient survival and treatment response more accurately than conventional methods. This approach has shown consistent predictive power across different racial and ethnic groups, addressing a common limitation of traditional biomarkers. The research, led by Dr. Kevin Gardner, focuses on integrating digital pathology, AI, and machine learning to create a comprehensive understanding of individual cancers.
Trendline Trendline
Verismo Therapeutics Expands Solid Tumor Treatment Pipeline with New CLDN6 Binder

Verismo Therapeutics Expands Solid Tumor Treatment Pipeline with New CLDN6 Binder

Verismo Therapeutics Expands Solid Tumor Treatment Pipeline with New CLDN6 Binder